<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE GlossaryTerm >
<GlossaryTerm id="CDR0000666675"><TermName>MET/VEGFR-2 inhibitor GSK1363089</TermName><TermPronunciation>(…. in-HIH-bih-ter ….)</TermPronunciation><TermDefinition><DefinitionText>A substance being studied in the treatment of cancer. MET/VEGFR-2 inhibitor GSK1363089 blocks enzymes involved in the growth and spread of tumor cells. It may also prevent the growth of new blood vessels that tumors  need to grow. It is a type of tyrosine kinase inhibitor and a type of antiangiogenesis agent. Also called foretinib and XL880.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></TermDefinition><MediaLink ref="CDR0000726006" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;MET/VEGFR-2 inhibitor GSK1363089&quot;" language="en" id="_3"/><MediaLink ref="CDR0000726007" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;inhibidor GSK1363089 de MET/VEGFR-2&quot;" language="es" id="_4"/><SpanishTermName>inhibidor GSK1363089 de MET/VEGFR-2</SpanishTermName><SpanishTermDefinition><DefinitionText>Sustancia en estudio para el tratamiento de cáncer.    El inhibidor MET/VEGFR-2 GSK1363089 bloquea las enzimas que participan en la formación y diseminación de células tumorales. También puede prevenir la formación de los vasos sanguíneos nuevos que los tumores necesitan para crecer. Es un tipo de inhibidor de la tirosina cinasa y un tipo de antiangiogénico. También se llama foretinib y XL880.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></SpanishTermDefinition><DateFirstPublished>2010-06-09</DateFirstPublished><DateLastModified>2010-06-09</DateLastModified></GlossaryTerm>
